Upgrade Now

Gilead Sciences's Remdesivir may cut Covid-19 risk of death by 62%

By Alexander Bueso

Date: Friday 10 Jul 2020

Gilead Sciences's Remdesivir may cut Covid-19 risk of death by 62%

(Sharecast News) - Gilead Sciences's Remdesivir antiviral treatment for the novel coronavirus may cut the risk of death by nearly two-thirds.
Third phase clinical trial data presented by the company at the 23rd International AIDS conference showed that the treatment was associated with a 62% reduction in the risk of mortality and an improvement in clinical recovery.

However, the biotechnology company said the finding needed to be confirmed through prospective clinical trials.

The company's Phase 3 SIMPLE-Severe study included 312 patients and a retrospective real-world sample of 818 patients who had endured the disease with a similar severity but had only been given standard of care treatment over the same period.

A majority of patients, 92.0%, were located in North America.

The same comparative analysis also showed that 74.4% of patients who were administered Remdesivir recovered by Day 14, against 59.0% for those receiving standard of care.

Over that same interval, the proportion of patients dosed with Gilead's retroviral who died was 7.6%, versus a 12.5% mortality rate for standard of care patients.


Email this article to a friend

or share it with one of these popular networks:

Top of Page